PL373593A1 - Zawierająca androgeny kompozycja farmaceutyczna isposób leczenia depresji - Google Patents

Zawierająca androgeny kompozycja farmaceutyczna isposób leczenia depresji

Info

Publication number
PL373593A1
PL373593A1 PL03373593A PL37359303A PL373593A1 PL 373593 A1 PL373593 A1 PL 373593A1 PL 03373593 A PL03373593 A PL 03373593A PL 37359303 A PL37359303 A PL 37359303A PL 373593 A1 PL373593 A1 PL 373593A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
treating depression
androgen
androgen pharmaceutical
depression
Prior art date
Application number
PL03373593A
Other languages
English (en)
Inventor
Robert E. Dudley
S.George Kottayil
Olivier Palatchi
Original Assignee
Unimed Pharmaceuticals, Inc.
Laboratoires Besins International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/098,232 external-priority patent/US20040002482A1/en
Priority claimed from US10/153,468 external-priority patent/US20040092494A9/en
Application filed by Unimed Pharmaceuticals, Inc., Laboratoires Besins International filed Critical Unimed Pharmaceuticals, Inc.
Publication of PL373593A1 publication Critical patent/PL373593A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03373593A 2002-03-15 2003-03-14 Zawierająca androgeny kompozycja farmaceutyczna isposób leczenia depresji PL373593A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/098,232 US20040002482A1 (en) 2000-08-30 2002-03-15 Androgen pharmaceutical composition and method for treating depression
US10/153,468 US20040092494A9 (en) 2000-08-30 2002-05-21 Method of increasing testosterone and related steroid concentrations in women

Publications (1)

Publication Number Publication Date
PL373593A1 true PL373593A1 (pl) 2005-09-05

Family

ID=33302446

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373593A PL373593A1 (pl) 2002-03-15 2003-03-14 Zawierająca androgeny kompozycja farmaceutyczna isposób leczenia depresji

Country Status (10)

Country Link
EP (1) EP1511494B1 (pl)
KR (1) KR20050074896A (pl)
CN (1) CN100544725C (pl)
AU (1) AU2003228314C1 (pl)
CA (1) CA2484164C (pl)
HU (1) HU230920B1 (pl)
MA (1) MA27690A1 (pl)
MX (1) MXPA04008988A (pl)
PL (1) PL373593A1 (pl)
WO (1) WO2004091631A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
CN116098908A (zh) * 2022-09-07 2023-05-12 宁夏医科大学 一种超生理剂量雄激素在改善前列腺癌中的应用
CN121617562B (zh) * 2026-02-03 2026-04-28 西安市第一医院 绝经后骨质疏松风险预测及中西医干预管理系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
KR20000070757A (ko) * 1997-02-07 2000-11-25 에버트 챨스 디 테스토스테론 결핍증이 나타나는 여성에게 테스토스테론을 보충하는 방법 및 이에 이용되는 조성물
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US5880117A (en) * 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR20030048021A (ko) * 2000-08-30 2003-06-18 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법

Also Published As

Publication number Publication date
EP1511494B1 (en) 2020-08-19
MA27690A1 (fr) 2006-01-02
AU2003228314C1 (en) 2009-03-26
EP1511494A4 (en) 2010-10-06
HU230920B1 (hu) 2019-03-28
MXPA04008988A (es) 2006-05-25
AU2003228314B8 (en) 2008-04-24
AU2003228314A1 (en) 2004-11-04
WO2004091631A1 (en) 2004-10-28
HUP0600855A2 (en) 2007-02-28
CN100544725C (zh) 2009-09-30
EP1511494A1 (en) 2005-03-09
CA2484164A1 (en) 2004-10-28
CN1652793A (zh) 2005-08-10
AU2003228314B2 (en) 2008-04-10
HUP0600855A3 (en) 2012-09-28
CA2484164C (en) 2009-12-29
KR20050074896A (ko) 2005-07-19

Similar Documents

Publication Publication Date Title
ZA200309676B (en) Cosmetic method and composition for enhancing attractiveness
AU2002329022A1 (en) Method and pharmaceutical composition for treating inflammation
GB0110288D0 (en) Composition and treatment method
EP1547755A4 (en) PIPE CONNECTION DEVICE AND TUBE CONNECTION METHOD
IL164219A0 (en) Method for treating and preventing hyparathyroidism
AU2003268032A8 (en) Composition and methods for treatment and screening
AUPS236902A0 (en) Composition and method for treating hypertension
AU2003219747A8 (en) Composition and method for coating medical devices
AU2003232044A8 (en) Composition and method for dermatological treatment
IL163981A0 (en) Androgen pharmaceutical composition and method fortreating depression
EP1684771A4 (en) COMPOSITION AND METHOD
IL161073A0 (en) Composition and method for treating diabetes
HUP0600855A2 (en) Androgen pharmaceutical composition for treating depression
AU2003213048A8 (en) Composition and method for protecting labile active components
AU2003262840A1 (en) Composition and method for treating skin
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
AU2003295574A8 (en) Method and compositions for temporarily incapaciting subjets
AU2003210474A8 (en) Composition and method for inhibiting hypersensitivity
AU2003275433A8 (en) Compositions and methods for treating pain
AU2003278935A8 (en) Method and composition for treating neurodegenerative disorders
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
GB0203528D0 (en) Process and composition
EP1539084A4 (en) COMPOSITION AND METHODS FOR TREATING SOFT NAILS
PL377357A1 (pl) Sposób i kompozycja do leczenia lęku
GB0229293D0 (en) Composition and method

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)